{
    "clinical_study": {
        "@rank": "166343", 
        "arm_group": {
            "arm_group_label": "Sitagliptin 100 mg/simvastatin 40 mg FDC", 
            "arm_group_type": "Experimental", 
            "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the safety and tolerability of sitagliptin 100\n      mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus\n      with inadequate glycemic control on metformin."
        }, 
        "brief_title": "A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                        "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "42"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "7.1", 
                                            "@value": "48.3"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "19"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "23"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "40.9", 
                                            "@value": "159.3"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Fasting Plasma Glucose (FPG)", 
                            "units": "mg/dL"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "27.2", 
                                            "@value": "109.6"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Low-density lipoprotein cholesterol (LDL-C)", 
                            "units": "mg/dL"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "36.4", 
                                            "@value": "195.2"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Total Cholesterol (TC)", 
                            "units": "md/dL"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "37.9", 
                                            "@value": "152.0"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "(Non-High-Density Lipoprotein Cholesterol (non-HDL-C)", 
                            "units": "mg/dL"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "152.5", 
                                            "@value": "225.3"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Triglycerides (TG)", 
                            "units": "mg/dL"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "11.9", 
                                            "@value": "43.1"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "High-Density Lipoprotein Cholesterol (HDL-C)", 
                            "units": "mg/dL"
                        }
                    ]
                }, 
                "population": "All participants enrolled"
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "42"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "-46.0", 
                                                    "@spread": "58.4", 
                                                    "@upper_limit": "-9.3", 
                                                    "@value": "-27.6"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Least Squares Mean", 
                                    "title": "Change From Baseline in Fasting Plasma Glucose (FPG)", 
                                    "units": "mg/dL"
                                }
                            ]
                        }, 
                        "population": "Full analysis set (FAS) defined as all participants who took at least one dose of study medication and had at least one baseline or post-baseline measurement.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 6", 
                        "title": "Change From Baseline in Fasting Plasma Glucose (FPG)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "42"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "2.7", 
                                                    "@upper_limit": "22.6", 
                                                    "@value": "9.5"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Who Experienced at Least One Adverse Event", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "All participants treated population defined as all enrolled participants who received at least one dose of study treatment.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Up to 8 weeks (including 14 days after final dose of study drug)", 
                        "title": "Percentage of Participants Who Experienced at Least One Adverse Event", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "42"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.", 
                                    "param": "Number", 
                                    "title": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "All participants treated population defined as all enrolled participants who received at least one dose of study treatment.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Up to 6 weeks", 
                        "title": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "41"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "-51.9", 
                                                    "@spread": "17.0", 
                                                    "@upper_limit": "-41.2", 
                                                    "@value": "-46.5"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Least Squares Mean", 
                                    "title": "Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)", 
                                    "units": "Percent change"
                                }
                            ]
                        }, 
                        "population": "FAS defined as all participants who took at least one dose of study medication and had both baseline and post-baseline measurements. One participant, who had no on-treatment data, was excluded from the FAS for the LDA analysis of LDL-C.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 6", 
                        "title": "Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "41"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "-37.3", 
                                                    "@upper_limit": "-30.0", 
                                                    "@value": "-33.7"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Least Squares Mean", 
                                    "title": "Change From Baseline in Total Cholesterol (TC)", 
                                    "units": "Percent change"
                                }
                            ]
                        }, 
                        "population": "FAS defined as all participants who took at least one dose of study medication and had both baseline and post-baseline measurements.\nOne participant, who had no on-treatment data, was excluded from the FAS for the LDA analysis of TC.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 6", 
                        "title": "Change From Baseline in Total Cholesterol (TC)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "41"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "-47.4", 
                                                    "@upper_limit": "-38.9", 
                                                    "@value": "-43.1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Least Squares Mean", 
                                    "title": "Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)", 
                                    "units": "Percent change"
                                }
                            ]
                        }, 
                        "population": "FAS defined as all participants who took at least one dose of study medication and had both baseline and post-baseline measurements. One participant, who had no on-treatment data, was excluded from the FAS for the LDA analysis of non-HDL-C.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 6", 
                        "title": "Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "41"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "-41.1", 
                                                    "@spread": "26.3", 
                                                    "@upper_limit": "-18.3", 
                                                    "@value": "-31.8"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Median", 
                                    "title": "Change From Baseline in Triglycerides (TG)", 
                                    "units": "Percent change"
                                }
                            ]
                        }, 
                        "population": "FAS defined as all participants who took at least one dose of study medication and had both baseline and post-baseline measurements. One participant, who had no on-treatment data, was excluded from the FAS.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 6", 
                        "title": "Change From Baseline in Triglycerides (TG)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                                "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "41"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "-5.0", 
                                                    "@upper_limit": "7.5", 
                                                    "@value": "1.3"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Least Squares Mean", 
                                    "title": "Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)", 
                                    "units": "Percent change"
                                }
                            ]
                        }, 
                        "population": "FAS defined as all participants who took at least one dose of study medication and had both baseline and post-baseline measurements. One participant, who had no on-treatment data, was excluded from the FAS for the LDA analysis of HDL-C.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 6", 
                        "title": "Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                        "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": {
                                "participants_list": {
                                    "participants": {
                                        "@count": "1", 
                                        "@group_id": "P1"
                                    }
                                }, 
                                "title": "Withdrawal by Subject"
                            }
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "42", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "41", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "ClinicalTrialsDisclosure@merck.com", 
                "name_or_title": "Senior Vice President, Global Clinical Development", 
                "organization": "Merck Sharp & Dohme Corp.", 
                "phone": "1-800-672-6372"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants continued on their pre-study dose of metformin (>=1000 mg per day).", 
                        "title": "Sitagliptin 100 mg/Simvastatin 40 mg FDC"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "3", 
                                            "@subjects_at_risk": "42"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "4", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "3", 
                                            "@subjects_at_risk": "42"
                                        }, 
                                        "sub_title": "Hypoglycemia"
                                    }
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA 16.0", 
                    "frequency_threshold": "5"
                }, 
                "time_frame": "Up to 8 weeks"
            }
        }, 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has type 2 diabetes mellitus\n\n          -  Male, or female who is not of reproductive potential or if of reproductive potential\n             agrees to abstain or use (or have their partner use) two acceptable methods of birth\n             control during the study and for 14 days after the last dose of study drug\n\n          -  Currently on metformin monotherapy (>=1000 mg per day) for at least 4 weeks prior to\n             study participation\n\n          -  Not on statin therapy or other lipid-lowering agent for at least 6 weeks prior to\n             study participation\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  History of 2 or more episodes of hypoglycemia resulting in seizure, coma or loss of\n             consciousness over the past 3 months\n\n          -  On a thiazolidinedione (TZD) within the past 12 weeks\n\n          -  Has been treated with a statin or other lipid-lowering agent within 6 weeks prior to\n             study participation\n\n          -  Is on or likely to require treatment with a prohibited medication (itraconazole,\n             ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease\n             inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil,\n             diltiazem, amlodipine, ranolazine, niacin)\n\n          -  Intends to consume >1.2 liters of grapefruit juice per day during the study\n\n          -  Is on or likely to require treatment for >=2 consecutive weeks or repeated courses of\n             corticosteroids (inhaled, nasal and topical corticosteroids are permitted)\n\n          -  Is on a weight loss program and not in the maintenance phase or has started a weight\n             loss medication or has undergone bariatric surgery within 12 months prior to study\n             participation\n\n          -  Has undergone a surgical procedure within 4 weeks of study participation or has\n             planned major surgery during the study\n\n          -  History of myopathy or rhabdomyolysis with any statin\n\n          -  History of myocardial infarction, unstable or stable angina, angioplasty, bypass\n             surgery, myocardial ischemia, peripheral artery disease, abdominal aortic aneurysm,\n             transient ischemic attacks, stroke of carotid origin or >50% obstruction of a carotid\n             artery\n\n          -  Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class\n             III or IV cardiac status\n\n          -  History of active liver disease (other than non-alcoholic steatosis) including\n             chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  Chronic progressive neuromuscular disorder\n\n          -  Human immunodeficiency virus (HIV)\n\n          -  Hematological disorder (such as aplastic anemia, myeloproliferative or\n             myelodysplastic syndromes, thrombocytopenia)\n\n          -  Currently being treated for hyperthyroidism or is on thyroid hormone replacement\n             therapy and has not been on a stable dose for at least 6 weeks\n\n          -  History of malignancy <=5 years prior to study participation, except for basal cell\n             or squamous cell skin cancer or in situ cervical cancer\n\n          -  Positive urine pregnancy test\n\n          -  Pregnant or breastfeeding, or is expecting to conceive or donate eggs during the\n             study, including 14 days following the last dose of study drug\n\n          -  User of recreational or illicit drugs or has had a recent history of drug abuse\n\n          -  Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or\n             engages in binge drinking"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "firstreceived_results_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702298", 
            "org_study_id": "0431D-312"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sitagliptin 100 mg/simvastatin 40 mg FDC", 
                "description": "Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks", 
                "intervention_name": "Sitagliptin 100 mg/simvastatin 40 mg FDC", 
                "intervention_type": "Drug", 
                "other_name": "MK-0431D"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg/simvastatin 40 mg FDC", 
                "description": "Participants will continue pre-study dose of metformin tablet(s) >=1000 per day", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fortamet\u00ae", 
                    "Glucophage\u00ae", 
                    "Glucophage\u00ae XR", 
                    "Glumetza\u00ae", 
                    "Riomet\u00ae", 
                    "Metgluco\u00ae", 
                    "Glycoran\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sitagliptin", 
                "Metformin", 
                "Simvastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 1, 2014", 
        "number_of_arms": "1", 
        "official_title": "An Open-label Study to Assess the Safety and Tolerability of MK-0431D for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Vietnam: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Change from baseline in FPG at Week 6 based on longitudinal data analysis (LDA) model including both baseline and post-baseline measurements as response variable and term time.", 
                "measure": "Change From Baseline in Fasting Plasma Glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.", 
                "measure": "Percentage of Participants Who Experienced at Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 weeks (including 14 days after final dose of study drug)"
            }, 
            {
                "description": "Participants who were discontinued from study drug due to an adverse event during the 6 weeks of treatment.", 
                "measure": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 weeks"
            }
        ], 
        "removed_countries": {
            "country": "Vietnam"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702298"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in LDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                "measure": "Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Change from baseline in TC was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                "measure": "Change From Baseline in Total Cholesterol (TC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Change from baseline in non-HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                "measure": "Change From Baseline in Non-high Density Lipoprotein Cholesterol (Non-HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Change from baseline in TG was measured as a percent change from baseline at Week 6 (median and distribution free 95% confidence interval).", 
                "measure": "Change From Baseline in Triglycerides (TG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }, 
            {
                "description": "Change from baseline in HDL-C was measured as a percent change from baseline at Week 6 based on LDA model including percent change from baseline as response variable and term time.", 
                "measure": "Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 6"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}